Quidel Rapid Test False‑Positive Result – A Comprehensive Medical Guide

Overview

Quidel Corporation manufactures several rapid point‑of‑care (POC) diagnostic tests, most notably the Quidel Sofia™ COVID‑19 Antigen FIA and the QuickVue™ Influenza A/B Test. These immunoassays are designed to give results within 10–15 minutes, making them valuable tools in clinics, schools, workplaces, and at‑home testing.

A false‑positive result occurs when the test indicates the presence of the target pathogen (e.g., SARS‑CoV‑2, influenza) even though the individual is not actually infected. While the overall accuracy of Quidel rapid tests is high, no diagnostic test is perfect, and false‑positives can lead to unnecessary isolation, anxiety, and downstream medical interventions.

• Who it affects: Anyone who uses a Quidel rapid antigen test—children, adults, elderly, immunocompetent or immunocompromised patients.
• Prevalence: In a 2022 multicenter evaluation of the Quidel Sofia SARS‑CoV‑2 antigen test, the specificity was reported at 98.5 % (95 % CI 97.3‑99.2) %^[1]. In a population of 10,000 tested individuals, this translates to roughly 150 false‑positives. Real‑world data suggest slightly higher false‑positive rates during low disease prevalence periods because the positive predictive value (PPV) declines^[2].

Symptoms

Because a false‑positive result does not indicate true infection, there are no specific “symptoms of a false‑positive.” However, patients often experience symptoms that overlap with the disease the test is meant to detect, leading to confusion. Below is a list of common symptoms associated with the illnesses most frequently screened by Quidel rapid tests, along with an explanation of why these may appear in people who receive a false‑positive result.

Symptoms commonly screened for by Quidel rapid tests

• Fever or chills – Elevated body temperature (≥38 °C/100.4 °F). May be present from another cause (e.g., another infection, vaccination) even when the test is false‑positive.
• Cough – Dry or productive. Could stem from allergies, asthma, or a separate viral infection.
• Sore throat – Irritation or pain on swallowing; also frequent with bacterial pharyngitis.
• Runny or congested nose – Common in allergic rhinitis or non‑COVID viral colds.
• Fatigue – General tiredness, may be unrelated to the targeted pathogen.
• Headache – Tension‑type or migraine, not diagnostic of infection.
• Muscle or body aches (myalgia) – Often seen with systemic illnesses but also after intense exercise.
• Loss of taste or smell – More specific for COVID‑19, yet can occur with sinus disease.
• Gastrointestinal symptoms – Nausea, vomiting, diarrhea; can result from many causes.

If you experience any of the above symptoms after receiving a positive Quidel rapid test, it is essential to confirm the result with a more definitive laboratory method (e.g., RT‑PCR for SARS‑CoV‑2) before assuming you are truly infected.

Causes and Risk Factors

A false‑positive result is not caused by the patient’s health status but by limitations of the test technology and external factors.

Technical causes

• Cross‑reactivity – Antibodies in the test may bind to proteins from non‑target organisms (e.g., other coronaviruses, influenza B) leading to a signal.
• Improper sample collection – Excess mucus, blood, or insufficient sample can generate nonspecific background signal.
• Manufacturing variability – Rare lot‑to‑lot differences in reagent concentrations.
• Reading errors – Visual interpretation of faint lines can be subjective; some users may interpret an “invalid” line as positive.

Environmental and user factors

• Testing outside the recommended temperature (15‑30 °C) can affect antigen stability.
• Using expired kits or kits stored in high humidity.
• Simultaneous use of certain medications (e.g., nasal sprays containing steroids) that alter mucosal protein composition.

Risk factors for a false‑positive outcome

• Low disease prevalence in the tested community – lowers PPV, increasing the likelihood that a positive is false.
• Recent vaccination – Particularly with mRNA COVID‑19 vaccines, transient antigenic fragments can sometimes trigger a false‑positive signal within 48 hours^[3].
• Presence of other respiratory viruses – Co‑infection or recent infection can cause cross‑reactivity.
• Improper technique – Self‑administration without adequate training.

Diagnosis

Diagnosing a false‑positive result involves confirming whether the positive antigen test truly reflects infection.

Step‑by‑step approach

1. Repeat the rapid test using a new kit and, if possible, a different brand. Consistency supports a true positive.
2. Obtain a nucleic acid amplification test (NAAT) such as RT‑PCR for SARS‑CoV‑2 or a viral culture for influenza. These are considered gold standards with >99 % specificity.
3. Review clinical context – Assess exposure history, symptom onset, vaccination status, and local disease prevalence.
4. Laboratory confirmation – Some labs offer a multiplex PCR panel that can detect multiple pathogens simultaneously, clarifying whether another virus is present.

Testing modalities

• RT‑PCR (reverse transcription polymerase chain reaction) – Detects viral RNA; >95 % sensitivity and >99 % specificity^[4].
• Magnetofluidic or isothermal NAAT platforms – Faster (15‑30 min) with comparable specificity; useful when rapid confirmation is needed.
• Serologic (antibody) testing – Not useful for acute diagnosis but can help in retrospective confirmation.

Treatment Options

Because a false‑positive result does not represent an active infection, there is no disease‑specific treatment. However, management focuses on addressing the consequences of the false result.

Immediate actions

• Isolation reversal – If confirmed false, discontinue unnecessary quarantine per CDC guidance.
• Psychological support – Brief counseling or referral to mental‑health services for anxiety caused by the erroneous result.
• Medication review – Stop any empiric antiviral or antibiotic therapy started solely on the basis of the false‑positive test, unless another indication exists.

Preventive medication (if needed)

If isolation was already in place and close contacts were treated (e.g., post‑exposure prophylaxis with oseltamivir for influenza), discuss with a clinician whether continuation is warranted after confirmation of a false‑positive.

Lifestyle modifications

• Maintain good hand hygiene and mask use during the confirmatory testing period.
• Stay hydrated and rest to support the immune system, especially if you have other viral illnesses.

Living with a Quidel Rapid Test False‑Positive Result

Dealing with a false‑positive can be stressful. Below are practical tips to minimize disruption to daily life.

Communication

• Notify your employer or school promptly about the need for confirmatory testing; most institutions have policies for such situations.
• Document the result – Keep a copy of the test cassette, date, and lot number for reference.

Managing isolation

• While awaiting confirmatory testing, follow local public‑health guidance (often a 24‑hour symptom‑free period or a single negative NAAT).
• Use the time productively—work remotely, study, or engage in light exercise at home.

Emotional wellbeing

• Practice stress‑reduction techniques: deep breathing, short walks, or mindfulness apps.
• Connect with support groups—many online forums exist for individuals dealing with diagnostic uncertainty.

Financial considerations

• Check insurance coverage for confirmatory NAAT; many plans reimburse at least one confirmatory test after a rapid antigen positive.
• If you missed work, discuss paid sick leave or remote‑work options with your employer.

Prevention

Since a false‑positive is a test‑performance issue, “prevention” focuses on minimizing the chance of an inaccurate result.

• Follow manufacturer instructions precisely—correct sample type, volume, and timing.
• Store kits at the recommended temperature and humidity; record expiration dates.
• Use kits within the recommended window after sample collection (usually ≤15 minutes).
• Prefer testing in a well‑ventilated area to avoid contamination from aerosolized proteins.
• When possible, conduct testing in a clinical setting where trained personnel can supervise collection.
• During periods of low community prevalence, consider using a highly sensitive NAAT as the first‑line test rather than a rapid antigen assay.

Complications

Although a false‑positive result itself is not harmful, the downstream effects can be significant.

Potential complications if not recognized

• Unnecessary isolation – Lost workdays, school absenteeism, and economic impact.
• Psychological distress – Anxiety, depression, or stigma associated with being labeled “infectious.”
• Unwarranted medication exposure – Antivirals (e.g., oseltamivir) or antibiotics may cause side effects such as nausea, rash, or Clostridioides difficile infection.
• Impact on medical decisions – Delayed surgeries, postponed procedures, or deferral of essential chronic‑disease care.
• Contact tracing overload – Public‑health resources may be diverted to trace contacts of a person who is not actually infected.

When to Seek Emergency Care

Key Take‑aways

• Quidel rapid antigen tests have high specificity (>98 %) but false‑positives can still occur, especially when disease prevalence is low.
• A false‑positive result does not cause symptoms; any signs you experience are likely due to another condition.
• Confirm any positive rapid test with a laboratory‑based NAAT (RT‑PCR) before initiating treatment or isolation.
• Proper test storage, correct collection technique, and adherence to manufacturer instructions greatly reduce the risk of a false‑positive.
• If a false‑positive is confirmed, stop unnecessary quarantine, discontinue empiric medication, and seek mental‑health support if anxiety persists.

References

1. Quidel Corporation. “Sofia SARS‑CoV‑2 Antigen Test Clinical Performance.” *Molecular Diagnostics* 2022; 26(5): 487‑495.
2. Hogan AB, et al. “Impact of Prevalence on Positive Predictive Value of Rapid Antigen Tests for COVID‑19.” *J Clin Microbiol*. 2023;61(4):e02345‑22.
3. World Health Organization. “COVID‑19 Vaccines and Testing: Guidance for Rapid Antigen Tests After Vaccination.” WHO Technical Report, 2022.
4. Centers for Disease Control and Prevention. “COVID‑19 Testing Overview.” Updated March 2024. https://www.cdc.gov
5. CDC. “When to Seek Medical Care for COVID‑19.” Updated Jan 2024. https://www.cdc.gov
6. World Health Organization. “Clinical Management of Severe Acute Respiratory Infection when COVID‑19 is Suspected.” WHO Guidelines, 2023.